Tracker

ETF universe handoff

Opening ETF evidence benchSynchronizing prices, risk metrics, holdings coverage, and source lineage

Company context

West Pharmaceutical Services, Inc.

NYSE:WST

Medical Specialties · benchmarked against Medical Specialties inside the XLV constituent company universe.

Active tabFinancial reports

Current readMixed

Last close359.47

1M return+0.51%

Open symbol page Watchlist context

OverviewVerdict, thesis map, and valuation setup.FundamentalsDrivers, trajectory, and business quality.Financial reportsStatement tables, sorting, filtering, and acceleration.Ex-ante forecastTarget price, dividend yield, and total return by horizon.FactorsCompany factor exposure, rank, and universe context.Market viewMomentum, catalysts, charts, and symbol packet.AttributionLarge-move causes, residuals, and research backlog.OwnershipSEC 13F holder flow, crowding, and manager changes.PeersPeer heatmap and closest comparables.

Tab scope

Raw financial statements

Financial reports

Source and lookbackStored financial report rows12 report snapshots; latest report May 11, 1:17 AM GMT+8.

Sample and caveat28 reported metrics across 4 sections.Use this tab for its stated job; heavier model packets stay on their own tabs.

Traditional statement tables

Financial reports

12 reports · latest May 11, 1:17 AM GMT+8

Distinct report rows12

Sections4

Metrics28

Coverage100%

CompanyWest Pharmaceutical Services, Inc.

Overview scoring

Fundamental overview

44/100 blended · 97/100 confidence · benchmark Closest peers

Blended fundamental score: Earnings 52/100; Cash flow 27/100; Balance sheet 65/100; Valuation 18/100.

Broad comparison

Cohort scorecard

Coverage-adjusted score with thinner cohorts automatically down-weighted

Cohort scorecard: Closest peers 45/100; Medical Specialties 45/100; Health Technology 40/100; XLV constituent company universe 41/100.

Selected company rank

Rank and percentile

Confidence-adjusted standing inside each cohort

Rank and percentile: Closest peers #10 of 13; Medical Specialties #20 of 24; Health Technology #36 of 41; XLV constituent company universe #51 of 59.

Section scoring matrix

Earnings, cash flow, balance sheet, and valuation

Heatmap score by cohort and statement section

Section scoring matrix: Closest peers Earnings 53/100; Cash flow 30/100; Balance sheet 65/100; Valuation 19/100.

Sort byFilter metrics

Specialist report review

Quant, PM, and risk-manager reads

Deterministic review lanes from stored report metrics

Quant review

Favorable acceleration13/24

FCF yield has the largest second-order move at -33.37%. 13 metrics are accelerating favorably and 11 are decelerating.

Fundamental PM review

Growth and cash quality4/5

EPS TTM is 7.48 with +10.11% latest change. The PM lane checks revenue, EPS, cash flow, and margin confirmation together.

Risk manager review

Risk controls need review4 watch items

Debt / Equity is 0.11 with +4.51% latest change. The risk lane checks leverage, liquidity, and cash-yield deterioration.

Indexed report history

Financial report trend chart

First visible report = 100

Financial report trend chart: Total revenue 3.1B; Revenue quarter 844.9M; Operating income TTM 690.9M; Operating margin +22.47%.

Second order change

Acceleration chart

Favorable acceleration means the latest move improved versus the prior move

Acceleration chart: Revenue quarter +4.61%; Operating income TTM +7.63%; Operating margin +9.51%; EPS TTM +9.49%.

PM / risk lens

Risk and quality radar

Directional score from change and acceleration

Risk and quality radar: Growth 63/100; Cash 36/100; Quality 75/100; Balance 22/100; Valuation 25/100.

Earnings

Metric trend table

10 of 10 metrics shown

Metric	Latest	Change	Acceleration	Trend	Samples
Total revenueRevenue	3.1B	+1.91%+57.5M	-0.03%+100K	improving	11
Revenue quarterRevenue	844.9M	+4.83%+38.9M	+4.61%+37.2M	accelerating	12
Revenue next quarterRevenue	839.2M	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Operating income TTMEarnings	690.9M	+8.53%+54.3M	+7.63%+48.6M	accelerating	11
Operating marginProfitability	+22.47%	+8.53%+1.77 pts	+9.51%+1.97 pts	accelerating	12
EPS TTMEarnings	7.48	+10.11%+0.69	+9.49%+0.64	accelerating	8
EPS next quarterEarnings	2.08	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Gross marginQuality	+36.27%	+0.97%+0.35 pts	+0.03%+0.02 pts	stable	12
Net marginQuality	+16.85%	+4.93%+0.79 pts	+6.40%+1.03 pts	accelerating	12
Gross-to-net conversionQuality	+46.45%	+3.92%+1.75 pts	+6.31%+2.84 pts	accelerating	12

Historical statement rows

Earnings report history

12 dated rows

Snapshot date	Total revenue	Revenue quarter	Revenue next quarter	Operating income TTM	Operating margin	EPS TTM	EPS next quarter	Gross margin	Net margin	Gross-to-net conversion
Jul 3, 2023	2.9B	754.2M	—	704.2M	+24.58%	—	—	+38.18%	+18.11%	+47.43%
Oct 2, 2023	2.9B	747.5M	—	707.7M	+24.19%	—	—	+38.13%	+19.12%	+50.14%
Jan 2, 2024	2.9B	732.1M	—	716.5M	+24.29%	—	—	+38.35%	+20.12%	+52.45%
Apr 1, 2024	2.9B	695.3M	—	676M	+23.08%	—	—	+37.28%	+19.42%	+52.08%
Jul 1, 2024	2.9B	702M	—	619.5M	+21.53%	7.03	—	+35.84%	+18.25%	+50.91%
Oct 7, 2024	2.9B	746.9M	—	596.2M	+20.73%	6.74	—	+35.00%	+17.37%	+49.62%
Jan 6, 2025	2.9B	748.5M	—	596.2M	+20.61%	6.69	—	+34.65%	+17.03%	+49.16%
Apr 7, 2025	2.9B	698.2M	—	597.6M	+20.64%	6.37	—	+34.66%	+16.13%	+46.55%
Jul 7, 2025	3B	766.2M	—	625M	+21.12%	6.68	—	+35.32%	+16.48%	+46.65%
Oct 6, 2025	3B	804.3M	—	630.9M	+20.91%	6.75	—	+35.59%	+16.30%	+45.79%
Jan 5, 2026	3.1B	806M	—	636.6M	+20.70%	6.79	—	+35.92%	+16.06%	+44.70%
May 11, 2026	3.1B	844.9M	839.2M	690.9M	+22.47%	7.48	2.08	+36.27%	+16.85%	+46.45%